Biosolution Co Ltd
086820
Company Profile
Business description
Biosolution Co Ltd is a Korean company offering Cell-Based Biotechnology. It is engaged in manufacturing and selling cell therapy products, and developing cell therapeutics technology. Its main areas include cell-based therapeutics with their background in somatic and stem cell technology, and the manufacturing, sales, and R&D of human tissue models for screening toxicity and efficacy with tissue engineering technology.
Contact
Gongneung-Ro 232, Nowon-gu
5th Floor, Room 519, Seoul Technopark
Seoul
KORT: +82 234468884
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
88
Stocks News & Analysis
stocks
Is this still an ASX share to own forever?
Find out how this defensive player has fared after earnings.
stocks
After earnings, is Nvidia stock a buy, a sell, or fairly valued?
No signs of a slowdown in demand for Nvidia’s chips, and the long-term picture looks bright.
stocks
Short-term pain for long-term gain for undervalued ASX share
Cost reductions lower our profit estimates but should lead to improved long-term outcomes.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,091.40 | 51.20 | 0.57% |
| CAC 40 | 7,698.92 | 20.79 | -0.27% |
| DAX 40 | 23,770.33 | 175.53 | 0.74% |
| Dow JONES (US) | 45,467.83 | 196.60 | 0.43% |
| FTSE 100 | 9,216.87 | 38.88 | 0.42% |
| HKSE | 25,058.51 | 284.92 | -1.12% |
| NASDAQ | 21,550.28 | 52.55 | 0.24% |
| Nikkei 225 | 42,580.27 | 641.38 | 1.53% |
| NZX 50 Index | 13,133.20 | 58.39 | 0.45% |
| S&P 500 | 6,470.06 | 21.80 | 0.34% |
| S&P/ASX 200 | 8,826.50 | 59.20 | 0.68% |
| SSE Composite Index | 3,765.88 | 47.68 | -1.25% |